APR:NSD-Apria Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 37.18

Change

-0.03 (-0.08)%

Market Cap

USD 1.32B

Volume

0.71M

Avg Analyst Target

USD 38.75 (+4.22%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Apria Inc (APR) Stock Analysis:
Based on the Apria Inc stock forecasts from 3 analysts, the average analyst target price for Apria Inc is USD 38.75 over the next 12 months. Apria Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apria Inc is Bullish , which is based on 9 positive signals and 3 negative signals. At the last closing, Apria Inc’s stock price was USD 37.18. Apria Inc’s stock price has changed by -0.06% over the past week, +4.53% over the past month and +0.00% over the last year.

About

Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

-7.84 (-2.88%)

USD96.29B 57.84 56.84
HOLX Hologic Inc

-0.86 (-1.21%)

USD17.76B 9.80 7.26
MASI Masimo Corporation

-10.53 (-4.71%)

USD11.77B 53.02 49.11
XRAY DENTSPLY SIRONA Inc

-1.16 (-2.15%)

USD11.51B 27.68 14.28
RGEN Repligen Corporation

-4.39 (-2.31%)

USD10.16B 87.49 73.96
NVCR NovoCure Limited

-4.53 (-6.57%)

USD7.39B 1,480.87 4,066.85
AZTA Azenta Inc

-2.35 (-2.88%)

USD5.76B 51.78 406.97
ICUI ICU Medical Inc

-5.54 (-2.60%)

USD5.00B 41.87 18.69
STAA STAAR Surgical Company

-5.15 (-6.89%)

USD3.56B 159.38 123.68
MMSI Merit Medical Systems Inc

-2.30 (-4.00%)

USD3.14B 72.72 25.40

ETFs Containing APR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.05% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.05% 100% A+ 98% A+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 1.32B 68% D+ 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.80 78% C+ 54% F
Price/Book Ratio 47.78 3% F 2% F
Price / Cash Flow Ratio 6.71 53% F 42% F
EV/EBITDA 5.91 92% A- 76% C
Management Effectiveness  
Return on Equity 82.29% 100% A+ 99% A+
Return on Invested Capital 15.91% 92% A- 85% B
Return on Assets 12.87% 97% A+ 95% A
Debt to Equity Ratio -1,428.69% 100% A+ 99% A+
Technical Ratios  
Short Ratio 3.09 51% F 38% F
Short Percent 7.64% 14% F 22% F
Beta -0.47 94% A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.